ARVN250117C12500
- 0.00
- 0.000.00%
Arvinas Newsroom
BofA Securities Maintains Arvinas(ARVN.US) With Buy Rating, Raises Target Price to $57
Analysts' Opinions Are Mixed on These Healthcare Stocks: Outset Medical (OM), Arvinas Holding Company (ARVN) and Innovent Biologics (OtherIVBXF)
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Buy Rating for Arvinas Holding Company Driven by Vepdeg's Promising Potential and Market Opportunity
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $48
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Evercore Initiates Arvinas(ARVN.US) With Buy Rating, Announces Target Price $110
Arvinas Holding Company (ARVN) Receives a Buy From Evercore ISI
Arvinas Analyst Ratings
H.C. Wainwright Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $87
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Promising Potential and Strong Efficacy of Arvinas Holding's Vepdeg+Abema Combination Drive Buy Rating
Piper Sandler Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $67
BMO Capital Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $88
Wells Fargo Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $60
Arvinas Holding's VERITAC-2 Trial Progress Drives Buy Rating Despite Adjusted Price Target
Arvinas Is Maintained at Outperform by BMO Capital
Arvinas Analyst Ratings
BMO Capital Maintains Arvinas(ARVN.US) With Buy Rating, Cuts Target Price to $88
Stephens Initiates Arvinas(ARVN.US) With Buy Rating, Announces Target Price $55